NeuSpera Medical, Inc., headquartered in San Jose, California, is a pioneering company in the field of neuromodulation technology, focusing on implantable medical devices to address chronic illnesses. Founded in 2014 by Alexander Yeh, the company is renowned for its development of ultra-miniaturized neuromodulation devices. NeuSpera has raised approximately $102 million over multiple funding rounds, with significant contributions from prominent investors such as Vertex Ventures HC, Treo Ventures, and others. The company aims to improve patient outcomes for conditions like urinary urge incontinence (UUI), which is often associated with overactive bladder (OAB).
| Attribute | Information |
|---|---|
| Founding Date | 2014 |
| Headquarters | San Jose, California, USA |
| Founders | Alexander J. Yeh |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Vertex Ventures HC, Treo Ventures, Action Potential VC |
| Industry | Medical Devices, Neuromodulation |
| Number of Employees | Approximately 8 |
NeuSpera Medical was formerly known as Vivonda Medical, founded in 2014 by Alexander Yeh. The company began its journey by focusing on neuromodulation devices that were significantly smaller than traditional options, leveraging patented mid-field powering technology. This focus on miniaturization was a direct application of Yeh's advanced research at Stanford University, where he developed the principles for wireless powering and communication for implantable devices. The company's early milestones included securing necessary funding and FDA approvals for its initial devices, laying a strong foundation for future innovations in medical technology.
NeuSpera Medical has positioned itself as a leader in the development of miniaturized implantable medical devices. The company is best known for its Neuspera Implantable Sacral Neuromodulation (SNM) System:
The company’s proprietary technology allows devices to perform effectively while being significantly smaller and more manageable, which reduces procedural complexity and improves patient outcomes. This technology has been pivotal in addressing conditions like urinary urge incontinence, which affects millions globally.
In 2024, NeuSpera Medical continues to focus on clinical development and commercial readiness of its SNM System. The company is actively engaged in the SANS-UUI pivotal trial, aimed at establishing this system as a superior treatment option for UUI. NeuSpera occupies a competitive position in the neuromodulation industry, offering unique advantages with its ultra-miniaturized, minimally invasive technology. Its competitive edge lies in the ability to deliver effective treatment options that integrate seamlessly into patients’ lives, providing both efficacy and convenience.
NeuSpera Medical stands out for its innovative approach to neuromodulation, harnessing cutting-edge technology to develop less invasive treatment options for chronic conditions. With significant investment backing and FDA milestones achieved, NeuSpera is poised to impact the medical device industry substantially. The company's focus on patient-centric solutions positions it well for continued growth and influence, particularly as it advances towards FDA approval and commercialization of the Neuspera System. As technology in medical devices progresses, NeuSpera's commitment to innovation and improvement of patient care sets a promising trajectory for future developments.